Results 211 to 220 of about 495,708 (385)
A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
Arthritis &Rheumatology, EarlyView.Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen +14 more
wiley +1 more source
Arthritis &Rheumatology, EarlyView.Objective The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair +14 more
wiley +1 more source
Transitioning from deceptive to nondeceptive placebo treatment to reduce pathological skin-picking. [PDF]
Discov Ment HealthSchienle A, Wilhelm J, Tanzmeister S.
europepmc +1 more source
Arthritis &Rheumatology, EarlyView.Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley +1 more source
Has the time come to stop using control groups in trials of psychosocial interventions? [PDF]
World PsychiatryCuijpers P.
europepmc +1 more source
, 2016 Kan man overhovedet stole på uddannelsesforskningen, når den ikke tager højde for den effect, forskeres og læreres entusiasme i forhold til en ny metode kan have for resultaterne?
openaire +2 more sources
Unraveling the mystery of placebo effect in research and practice: An update. [PDF]
Perspect Clin ResMishra P, Bhargava S.
europepmc +1 more source